Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Par Pharmaceutical Companies, a developer of generic drugs and branded pharmaceuticals, has entered into a supply and distribution agreement with AstraZeneca in the US to market budesonide inhalation suspension, which is a generic form of AstraZeneca's Pulmicort Respules indicated for the maintenance treatment of asthma.
Subscribe to our email newsletter
Par began shipping 0.25mg/2ml and 0.5mg/2ml to the trade. Budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to eight years of age.